LeMaitre Vascular: Conflicting Cues from Management and Markets

Investor focus has sharpened on LeMaitre Vascular following a third-quarter earnings report that delivered mixed results and a series of notable insider stock transactions. The interplay between revenue growth, a downward revision in guidance, and executive buying and selling paints a complex picture for the medical device firm’s near-term trajectory.

The company disclosed its Q3 2025 financial results on November 6. Revenue reached $61.05 million, representing a year-over-year increase of 11.4%. While this demonstrates continued top-line expansion, the figure came in approximately 2% below consensus analyst estimates. Conversely, earnings per share (EPS) managed to exceed market expectations. The more significant concern for investors emerged from management’s updated full-year outlook, which was Read more...